J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
J&J is washing its hands of the Phase III Clostridium difficile-associated diarrhea program for the antibiotic cadazolid.
The pharma giant obtained rights to the antibiotic in their $30 billion buyout of Actelion. But as the deal was being completed, cadazolid floundered — hitting the goal posts in one study but missing in another — after recruiting 1,263 patients to compare 250 mg of cadazolid twice daily against 4 daily doses of 125 mg vancomycin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.